You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Immune-mediated neuropathies induced by immunosuppressive treatment
  1. Satoshi Kuwabara,
  2. Sonoko Misawa
  1. Department of Neurology, Graduate School of Medicine, Chiba University
  1. Correspondence to Dr Satoshi Kuwabara, Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan; kuwabara-s{at}faculty.chiba-u.jp

https://doi.org/10.1136/jnnp-2012-302876

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy and the efficacy of immunosuppressive or immunomodulating treatments with corticosteroids, intravenous immunoglobulin and plasma exchange has been established.1 2 For patients refractory to these conventional therapies, other immunosuppressants such as cyclophosphamide, ciclosporin rituximab and tumour necrosis factor (TNF)-α antagonists have been trialed.3 4

    Conversely, several studies have established that immunosuppressive agents may trigger the development of CIDP. Recent examples include CIDP induced by TNF-α antagonists such as infliximab and etanercept.5 Separately, therapy with the TNF-α antagonists for rheumatoid …

    View Full Text

    Footnotes

    • Linked article 302374.

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles